| First Author | Jeong MH | Year | 2014 |
| Journal | PLoS One | Volume | 9 |
| Issue | 3 | Pages | e91039 |
| PubMed ID | 24614171 | Mgi Jnum | J:215123 |
| Mgi Id | MGI:5604684 | Doi | 10.1371/journal.pone.0091039 |
| Citation | Jeong MH, et al. (2014) beta-Lapachone ameliorates lipotoxic cardiomyopathy in acyl CoA synthase transgenic mice. PLoS One 9(3):e91039 |
| abstractText | Lipotoxic cardiomyopathy is caused by myocardial lipid accumulation and often occurs in patients with diabetes and obesity. This study investigated the effects of beta-lapachone (beta-lap), a natural compound that activates Sirt1 through elevation of the intracellular NAD+ level, on acyl CoA synthase (ACS) transgenic (Tg) mice, which have lipotoxic cardiomyopathy. Oral administration of beta-lap to ACS Tg mice significantly attenuated heart failure and inhibited myocardial accumulation of triacylglycerol. Electron microscopy and measurement of mitochondrial complex II protein and mitochondrial DNA revealed that administration of beta-lap restored mitochondrial integrity and biogenesis in ACS Tg hearts. Accordingly, beta-lap administration significantly increased the expression of genes associated with mitochondrial biogenesis and fatty acid metabolism that were down-regulated in ACS Tg hearts. beta-lap also restored the activities of Sirt1 and AMP-activated protein kinase (AMPK), the two key regulators of metabolism, which were suppressed in ACS Tg hearts. In H9C2 cells, beta-lap-mediated elevation of AMPK activity was retarded when the level of Sirt1 was reduced by transfection of siRNA against Sirt1. Taken together, these results indicate that beta-lap exerts cardioprotective effects against cardiac lipotoxicity through the activation of Sirt1 and AMPK. beta-lap may be a novel therapeutic agent for the treatment of lipotoxic cardiomyopathy. |
